| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
|
JAMA
|
2013
|
3.78
|
|
2
|
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
|
Crit Care Med
|
2004
|
1.80
|
|
3
|
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.
|
Am J Respir Crit Care Med
|
2011
|
1.65
|
|
4
|
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
|
Crit Care Med
|
2014
|
1.56
|
|
5
|
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
|
Crit Care
|
2010
|
0.90
|
|
6
|
Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study.
|
J Infect Dis
|
2013
|
0.85
|